オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - entecavir monohydrate is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir monohydrate is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir monohydrate is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 800 microgram - tablet, film coated - excipient ingredients: hyprolose; iron oxide black; carnauba wax; titanium dioxide; maize starch; hypromellose; mannitol; propylene glycol; magnesium stearate; iron oxide yellow - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1400 microgram - tablet, film coated - excipient ingredients: mannitol; maize starch; hyprolose; hypromellose; propylene glycol; magnesium stearate; titanium dioxide; carnauba wax; iron oxide yellow - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1600 microgram - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; magnesium stearate; mannitol; iron oxide yellow; carnauba wax; hyprolose; maize starch; propylene glycol; iron oxide black; iron oxide red - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1200 microgram - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; maize starch; propylene glycol; iron oxide red; mannitol; hypromellose; magnesium stearate; carnauba wax; iron oxide black - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1000 microgram - tablet, film coated - excipient ingredients: mannitol; hypromellose; titanium dioxide; maize starch; hyprolose; magnesium stearate; propylene glycol; iron oxide red; carnauba wax; iron oxide yellow - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 200 microgram - tablet, film coated - excipient ingredients: iron oxide yellow; carnauba wax; maize starch; magnesium stearate; hyprolose; propylene glycol; mannitol; titanium dioxide; hypromellose - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 400 microgram - tablet, film coated - excipient ingredients: hyprolose; hypromellose; carnauba wax; magnesium stearate; mannitol; maize starch; propylene glycol; titanium dioxide; iron oxide red - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms